We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
TPST-1120, a first-in-class, oral, selective PPARโบ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized...
Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in...
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.39 | 12.5806451613 | 3.1 | 3.7164 | 3.08 | 426971 | 3.42389536 | CS |
4 | -0.43 | -10.9693877551 | 3.92 | 6 | 3.0611 | 1715301 | 4.79473004 | CS |
12 | -0.58 | -14.2506142506 | 4.07 | 6 | 3.03 | 981500 | 4.37781614 | CS |
26 | -0.76 | -17.8823529412 | 4.25 | 6 | 2.7606 | 1677996 | 3.8145539 | CS |
52 | 1.31 | 60.0917431193 | 2.18 | 9.77 | 0.17 | 3155705 | 5.86069529 | CS |
156 | -10.32 | -74.7284576394 | 13.81 | 41 | 0.17 | 1218460 | 6.40050943 | CS |
260 | -10.32 | -74.7284576394 | 13.81 | 41 | 0.17 | 1218460 | 6.40050943 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions